Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 14.54% is 195% above its 5-year average of -15.37%, near the high end of its 5-year range (-31.90%–14.54%).
12216.67% above its 12-month average of -0.12%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
14.54%
RETURN ON ASSETS (ROA) AVG TTM
-0.12%
RETURN ON ASSETS (ROA) AVG 3Y
-10.91%
RETURN ON ASSETS (ROA) AVG 5Y
-15.37%
RETURN ON ASSETS (ROA) AVG 10Y
-23.24%
RETURN ON ASSETS (ROA) AVG 15Y
-25.66%
RETURN ON ASSETS (ROA) AVG 20Y
-22.31%
CURRENT VS TTM AVG
+12216.67%
CURRENT VS 3Y AVG
+233.30%
CURRENT VS 5Y AVG
+194.59%
CURRENT VS 10Y AVG
+162.57%
CURRENT VS 15Y AVG
+156.66%
CURRENT VS 20Y AVG
+165.16%
SECTOR MEDIAN · HEALTHCARE
5.18%
median of 88 covered companies
CURRENT VS SECTOR MEDIAN
+180.69%
vs the sector median at left
Alnylam Pharmaceuticals, Inc.
Market Cap
$31.73B
Return on Assets (ROA)
14.54%
TTM Avg
-0.12%
3Y Avg
-10.91%
5Y Avg
-15.37%
Market Cap
$31.99B
Return on Assets (ROA)
-6.14%
TTM Avg
-2.29%
3Y Avg
0.04%
5Y Avg
0.75%
Market Cap
$32.28B
Return on Assets (ROA)
2.60%
TTM Avg
5.11%
3Y Avg
6.74%
5Y Avg
8.29%
Market Cap
$32.40B
Return on Assets (ROA)
4.27%
TTM Avg
5.83%
3Y Avg
5.87%
5Y Avg
14.86%
Market Cap
$32.42B
Return on Assets (ROA)
17.35%
TTM Avg
17.37%
3Y Avg
16.33%
5Y Avg
15.33%
Market Cap
$31.02B
Return on Assets (ROA)
0.67%
TTM Avg
13.34%
3Y Avg
15.53%
5Y Avg
17.15%
Market Cap
$29.83B
Return on Assets (ROA)
1.76%
TTM Avg
3.17%
3Y Avg
1.75%
5Y Avg
1.75%
Market Cap
$34.27B
Return on Assets (ROA)
15.49%
TTM Avg
11.04%
3Y Avg
9.26%
5Y Avg
8.83%
Market Cap
$34.86B
Return on Assets (ROA)
16.99%
TTM Avg
17.06%
3Y Avg
15.57%
5Y Avg
14.60%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | $31.73B | 14.54% | -0.12% | -10.91% | -15.37% |
| Centene Corp. (CNC)vs › | $31.99B | -6.14% | -2.29% | 0.04% | 0.75% |
| Biogen Inc. (BIIB)vs › | $32.28B | 2.60% | 5.11% | 6.74% | 8.29% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $32.40B | 4.27% | 5.83% | 5.87% | 14.86% |
| Zoetis Inc. (ZTS)vs › | $32.42B | 17.35% | 17.37% | 16.33% | 15.33% |
| Waters Corporation (WAT)vs › | $31.02B | 0.67% | 13.34% | 15.53% | 17.15% |
| Medline Inc. (MDLN)vs › | $29.83B | 1.76% | 3.17% | 1.75% | 1.75% |
| DexCom, Inc. (DXCM)vs › | $34.27B | 15.49% | 11.04% | 9.26% | 8.83% |
| ResMed Inc. (RMD)vs › | $34.86B | 16.99% | 17.06% | 15.57% | 14.60% |
| Alcon Inc. (ALC)vs › | $35.12B | 2.06% | 3.23% | 2.72% | 1.72% |
ROA
14.5%
ROE
59.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 6.32% |
| 2024-12-31 | -6.56% |
| 2023-12-31 | -11.49% |
| 2022-12-31 | -31.90% |
| 2021-12-31 | -23.41% |
| 2020-12-31 | -25.19% |
| 2019-12-31 | -37.00% |
| 2018-12-31 | -48.36% |
| 2017-12-31 | -24.61% |
| 2016-12-31 | -32.48% |
| 2015-12-31 | -20.92% |
| 2014-12-31 | -33.38% |
| 2013-12-31 | -21.22% |
| 2012-12-31 | -36.87% |
| 2011-12-31 | -20.45% |
| 2010-12-31 | -11.07% |
| 2009-12-31 | -9.89% |
| 2008-12-31 | -4.73% |
| 2007-12-31 | -17.31% |
| 2006-12-31 | -14.42% |
| 2005-12-31 | -43.63% |
| 2004-12-31 | -49.40% |
| 2003-12-31 | -71.15% |
| 2002-12-31 | -25.67% |
